{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:40Z","timestamp":1789154320244,"version":"build-2803163510"},"reference-count":160,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.0363","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T16:01:23Z","timestamp":1583337683000},"page":"e200363","source":"Crossref","is-referenced-by-count":91,"title":["Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials"],"prefix":"10.1001","volume":"3","author":[{"given":"Alyson","family":"Haslam","sequence":"first","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Herrera-Perez","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gill","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health & Science University, Portland"},{"name":"Division of General Medicine, Department of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"1","key":"zoi200030r1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11585530-000000000-00000","article-title":"Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond.","volume":"4","author":"Baldwin","year":"2011","journal-title":"Patient"},{"issue":"12","key":"zoi200030r2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"zoi200030r3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi200030r4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi200030r5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(18)30195-5","article-title":"Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.","volume":"19","author":"Sch\u00e4fer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi200030r7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi200030r8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.","volume":"19","author":"Iveson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi200030r9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200030r10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study.","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","article-title":"Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.","volume":"19","author":"Colleoni","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi200030r14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi200030r15","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi200030r16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi200030r17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi200030r18","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi200030r19","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi200030r20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","article-title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi200030r21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","article-title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.","volume":"18","author":"Duchesne","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial.","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial.","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi200030r29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi200030r30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S1470-2045(17)30404-7","article-title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK\/05\/19): a multicentre, phase 3, open-label, randomised, controlled trial.","volume":"18","author":"Cameron","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi200030r32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi200030r33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi200030r34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"18","author":"Souli\u00e8res","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200030r35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200030r36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi200030r38","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S1470-2045(16)30305-9","article-title":"Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.","volume":"17","author":"Reijneveld","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r39","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S1470-2045(16)30120-6","article-title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.","volume":"17","author":"de Boer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r41","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi200030r42","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","article-title":"Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.","volume":"17","author":"Cella","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r44","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(16)00173-X","article-title":"Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.","volume":"17","author":"Bendixen","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi200030r46","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi200030r47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi200030r48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.","volume":"17","author":"Trnen\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi200030r49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi200030r50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200030r51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi200030r52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1470-2045(15)00461-1","article-title":"Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.","volume":"17","author":"Glover","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","article-title":"Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.","volume":"17","author":"Takashima","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200030r54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi200030r55","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi200030r56","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial.","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi200030r57","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi200030r58","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S1470-2045(15)00199-0","article-title":"Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial.","volume":"16","author":"Chow","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi200030r59","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S1470-2045(15)00332-0","article-title":"Etirinotecan pegol (NKTR-102) versus treatment of physician\u2019s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.","volume":"16","author":"Perez","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi200030r60","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi200030r61","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi200030r62","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi200030r63","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi200030r64","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi200030r65","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r66","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi200030r67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"zoi200030r68","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","article-title":"Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial.","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi200030r69","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial.","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi200030r70","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer.","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi200030r71","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1200\/JCO.2017.77.5817","article-title":"Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11\/DLCRG-02 study.","volume":"36","author":"De Ruysscher","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi200030r72","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial.","volume":"36","author":"Porceddu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi200030r73","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer.","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi200030r74","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase iii study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy.","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi200030r75","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO.2017.76.0611","article-title":"Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma.","volume":"36","author":"Grill","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.2017.74.7824","article-title":"Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE.","volume":"36","author":"Johnston","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r77","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.2017.75.2170","article-title":"Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial.","volume":"36","author":"Cella","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi200030r78","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.2017.75.2931","article-title":"Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9).","volume":"36","author":"Aparicio","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200030r79","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JCO.2017.75.7500","article-title":"Quality of life from Canadian Cancer Trials Group MA.17R: a randomized trial of extending adjuvant letrozole to 10 years.","volume":"36","author":"Lemieux","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi200030r80","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200030r81","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200030r82","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202.","volume":"36","author":"Henry","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi200030r83","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2017.73.7718","article-title":"Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial.","volume":"36","author":"Noordman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"35","key":"zoi200030r84","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma.","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"31","key":"zoi200030r85","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1200\/JCO.2017.72.2538","article-title":"Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase III trial (CLOG1302 study).","volume":"35","author":"Zhang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi200030r86","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study.","volume":"35","author":"Pignata","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi200030r87","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA.","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi200030r88","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer\u2014PROSELICA.","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi200030r89","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial.","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi200030r90","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2016.70.7828","article-title":"Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer.","volume":"35","author":"Jones","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r91","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","article-title":"Phase III randomized study of 4 weeks of high-dose interferon-a-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).","volume":"35","author":"Agarwala","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200030r92","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial.","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200030r93","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","article-title":"Randomized prospective biomarker trial of ercc1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 trial (ET).","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi200030r94","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study.","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200030r95","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome.","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"36","key":"zoi200030r96","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1200\/JCO.2016.67.1891","article-title":"Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or -refractory ovarian cancer.","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"32","key":"zoi200030r97","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.","volume":"34","author":"Stewart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"32","key":"zoi200030r98","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy.","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"issue":"30","key":"zoi200030r99","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial.","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi200030r100","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk Non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents.","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi200030r101","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial.","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi200030r102","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer.","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi200030r103","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1200\/JCO.2015.65.6843","article-title":"Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study.","volume":"34","author":"Segelov","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"zoi200030r104","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial.","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi200030r105","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991.","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"zoi200030r106","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","article-title":"Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial.","volume":"34","author":"Herrlinger","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"zoi200030r107","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function trial.","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi200030r108","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study.","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi200030r109","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r110","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer.","volume":"34","author":"Melosky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi200030r111","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.2015.62.1474","article-title":"Volasertib versus chemotherapy in platinum-resistant or -refractory ovarian cancer: a randomized phase II Groupe des Investigateurs Nationaux pour l\u2019Etude des Cancers de l\u2019Ovaire Study.","volume":"34","author":"Pujade-Lauraine","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200030r112","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2015.63.8221","article-title":"Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain.","volume":"34","author":"Fallon","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi200030r113","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2014a randomized phase III trial.","volume":"34","author":"Hecht","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi200030r114","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial.","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"35","key":"zoi200030r115","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","article-title":"Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study.","volume":"33","author":"Harrington","year":"2015","journal-title":"J Clin Oncol"},{"issue":"35","key":"zoi200030r116","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","article-title":"Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09\/10.","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi200030r117","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","article-title":"Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III Dermatologic Cooperative Oncology Group trial.","volume":"33","author":"Mohr","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi200030r118","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","article-title":"Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed.","volume":"33","author":"Hurwitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"30","key":"zoi200030r119","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","article-title":"A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial.","volume":"33","author":"Goetsch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi200030r120","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1200\/JCO.2015.61.6722","article-title":"Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial.","volume":"33","author":"Borget","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi200030r121","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group.","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi200030r122","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1200\/JCO.2014.57.8724","article-title":"Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3\/MRC PR07 randomized trial.","volume":"33","author":"Brundage","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi200030r123","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.2014.60.3217","article-title":"Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma.","volume":"33","author":"Taphoorn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200030r124","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial.","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi200030r125","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamaoncol.2016.5202","article-title":"Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial.","volume":"3","author":"Cirkel","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200030r126","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial.","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi200030r127","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2016.4510","article-title":"Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial.","volume":"3","author":"Siu","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi200030r128","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial.","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200030r129","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial.","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi200030r130","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamaoncol.2015.2666","article-title":"Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial.","volume":"1","author":"Shaitelman","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi200030r131","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1200\/JCO.2017.74.8244","article-title":"Restoring Body Image After Cancer (ReBIC): results of a randomized controlled trial.","volume":"36","author":"Esplen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r132","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2017.74.8491","article-title":"Web-based stress management for newly diagnosed patients with cancer (STREAM): a randomized, wait-list controlled intervention study.","volume":"36","author":"Urech","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200030r133","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1200\/JCO.2017.73.7221","article-title":"Role of patient coping strategies in understanding the effects of early palliative care on quality of life and mood.","volume":"36","author":"Greer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"32","key":"zoi200030r134","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial.","volume":"35","author":"El-Jawahri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi200030r135","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.2016.70.5301","article-title":"Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: the SWORD study, a randomized controlled trial.","volume":"35","author":"van de Wal","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi200030r136","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.2016.68.9497","article-title":"Randomized controlled trial of survivorship care plans among low-income, predominantly latina breast cancer survivors.","volume":"35","author":"Maly","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi200030r137","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1200\/JCO.2016.69.6021","article-title":"Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial.","volume":"35","author":"Hummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200030r138","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1200\/JCO.2016.70.5046","article-title":"Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial.","volume":"35","author":"Temel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi200030r139","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/JCO.2016.68.8788","article-title":"Mindfulness-based cognitive therapy in advanced prostate cancer: a randomized controlled trial.","volume":"35","author":"Chambers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi200030r140","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2016.67.8201","article-title":"Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy.","volume":"35","author":"Bray","year":"2017","journal-title":"J Clin Oncol"},{"issue":"36","key":"zoi200030r141","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","article-title":"Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial.","volume":"34","author":"Dieng","year":"2016","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi200030r142","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1200\/JCO.2015.65.0770","article-title":"Efficacy of mindfulness-based cognitive therapy on late post-treatment pain in women treated for primary breast cancer: a randomized controlled trial.","volume":"34","author":"Johannsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi200030r143","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.2015.65.7874","article-title":"Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial.","volume":"34","author":"Lengacher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi200030r144","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2015.65.9557","article-title":"Randomized noninferiority trial of telephone delivery of BRCA1\/2 genetic counseling compared with in-person counseling: 1-year follow-up.","volume":"34","author":"Kinney","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200030r145","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"31","key":"zoi200030r146","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1200\/JCO.2014.60.3399","article-title":"Impact of an automatically generated cancer survivorship care plan on patient-reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial.","volume":"33","author":"Nicolaije","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi200030r147","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1200\/JCO.2013.54.9386","article-title":"BREATH: web-based self-management for psychological adjustment after primary breast cancer\u2014results of a multicenter randomized controlled trial.","volume":"33","author":"van den Berg","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi200030r148","first-page":"92","article-title":"Effect of a patient-centered communication intervention on oncologist-patient communication, quality of life, and health care utilization in advanced cancer: the VOICE randomized clinical trial.","volume":"3","author":"Epstein","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"zoi200030r149","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1001\/jamaoncol.2016.1867","article-title":"Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: a randomized clinical trial.","volume":"2","author":"Zick","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi200030r150","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jamaoncol.2015.5252","article-title":"Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial.","volume":"2","author":"Grudzen","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi200030r151","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician\u2019s choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial.","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA Oncol"},{"issue":"24","key":"zoi200030r152","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1158\/1078-0432.CCR-10-1277","article-title":"Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?","volume":"16","author":"Fojo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"zoi200030r153","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization.","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"3","key":"zoi200030r154","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines.","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi200030r155","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"15","key":"zoi200030r156","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1200\/JCO.2018.36.15_suppl.6573","article-title":"Prevalence of quality of life (QoL) outcomes and association with survival in cancer clinical trials.","volume":"36","author":"Gyawali","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi200030r157","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrc930","article-title":"Quality of life: a new perspective for cancer patients.","volume":"2","author":"Fallowfield","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"zoi200030r158","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"18","key":"zoi200030r159","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1200\/JCO.2000.18.18.3295","article-title":"How are you feeling? who wants to know? patients\u2019 and oncologists\u2019 preferences for discussing health-related quality-of-life issues.","volume":"18","author":"Detmar","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi200030r160","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1053-4296(03)00029-8","article-title":"Quality of life in oncology trials: a clinical guide.","volume":"13","author":"Movsas","year":"2003","journal-title":"Semin Radiat Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2761989\/haslam_2020_oi_200030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T16:01:26Z","timestamp":1583337686000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2761989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0363","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}